Proteasome Inhibition Overcomes ALK-TKI Resistance in
Anaplastic Lymphoma Kinase
/ genetics
Animals
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Apoptosis
Biomarkers, Tumor
/ genetics
Boron Compounds
/ administration & dosage
Carbazoles
/ administration & dosage
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Cell Proliferation
Crizotinib
/ administration & dosage
Drug Resistance, Neoplasm
Gene Expression Regulation, Neoplastic
Gene Rearrangement
Glycine
/ administration & dosage
Humans
Lung Neoplasms
/ drug therapy
Male
Mice
Mice, SCID
Mutation
Piperidines
/ administration & dosage
Prognosis
Proteasome Endopeptidase Complex
/ chemistry
Protein Kinase Inhibitors
/ pharmacology
Proto-Oncogene Proteins c-bcl-2
/ genetics
Survival Rate
Tumor Cells, Cultured
Tumor Suppressor Protein p53
/ genetics
Xenograft Model Antitumor Assays
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
received:
31
08
2020
revised:
30
10
2020
accepted:
08
12
2020
pubmed:
15
12
2020
medline:
11
2
2022
entrez:
14
12
2020
Statut:
ppublish
Résumé
In We used integrated clinical and next-generation sequencing data generated in a nationwide lung cancer genome screening project (LC-SCRUM-Japan). In 90 patients with These clinical and preclinical results indicate concomitant
Identifiants
pubmed: 33310890
pii: 1078-0432.CCR-20-2853
doi: 10.1158/1078-0432.CCR-20-2853
doi:
Substances chimiques
Biomarkers, Tumor
0
Boron Compounds
0
Carbazoles
0
PMAIP1 protein, human
0
Piperidines
0
Protein Kinase Inhibitors
0
Proto-Oncogene Proteins c-bcl-2
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Crizotinib
53AH36668S
ixazomib
71050168A2
ALK protein, human
EC 2.7.10.1
Anaplastic Lymphoma Kinase
EC 2.7.10.1
Proteasome Endopeptidase Complex
EC 3.4.25.1
alectinib
LIJ4CT1Z3Y
Glycine
TE7660XO1C
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1410-1420Informations de copyright
©2020 American Association for Cancer Research.
Références
Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–6.
Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017;390:29–39.
Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6:1118–33.
Christopoulos P, Dietz S, Kirchner M, Volckmar AL, Endris V, Neumann O, et al. Detection of TP53 mutations in tissue or liquid rebiopsies at progression identifies ALK+ lung cancer patients with poor survival. Cancers. 2019;11:124.
Christopoulos P, Kirchner M, Bozorgmehr F, Endris V, Elsayed M, Budczies J, et al. Identification of a highly lethal V3(+) TP53(+) subset in ALK(+) lung adenocarcinoma. Int J Cancer. 2019;144:190–9.
Kron A, Alidousty C, Scheffler M, Merkelbach-Bruse S, Seidel D, Riedel R, et al. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann Oncol. 2018;29:2068–75.
Speidel D. The role of DNA damage responses in p53 biology. Arch Toxicol. 2015;89:501–17.
Rieber M, Strasberg-Rieber M. Hypoxia, Mn-SOD and H(2)O(2) regulate p53 reactivation and PRIMA-1 toxicity irrespective of p53 status in human breast cancer cells. Biochem Pharmacol. 2012;84:1563–70.
Li D, Marchenko ND, Moll UM. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ. 2011;18:1904–13.
Qin JZ, Stennett L, Bacon P, Bodner B, Hendrix MJ, Seftor RE, et al. p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Mol Cancer Ther. 2004;3:895–902.
Nanjo S, Nakagawa T, Takeuchi S, Kita K, Fukuda K, Nakada M, et al. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line. Cancer Sci. 2015;106:244–52.
Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami TA, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011;19:679–90.
Wong RP, Tsang WP, Chau PY, Co NN, Tsang TY, Kwok TT. p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3. Mol Cancer Ther. 2007;6:1054–61.
Albert MC, Brinkmann K, Kashkar H. Noxa and cancer therapy: tuning up the mitochondrial death machinery in response to chemotherapy. Mol Cell Oncol. 2014;1:e29906.
Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res. 2005;65:6282–93.
Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538:477–82.
Yoshida T, Oya Y, Tanaka K, Shimizu J, Horio Y, Kuroda H, et al. Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer. J Clin Oncol. 2016;34:3383–9.
Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX Study. J Thorac Oncol. 2019;14:1233–43.
Hochstrasser M. Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol. 1995;7:215–23.
Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood. 2009;114:1046–52.
Fribley A, Zeng Q, Wang CY.. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol. 2004;24:9695–704.
Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, et al. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2006;24:5025–33.
Huang Z, Wu Y, Zhou X, Xu J, Zhu W, Shu Y, et al. Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials. Future Oncol. 2014;10:1795–807.
Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2019;393:253–64.
Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621–34.
Labbé C, Cabanero M, Korpanty GJ, Tomasini P, Doherty MK, Mascaux C, et al. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Lung Cancer. 2017;111:23–9.
Jiao XD, Qin BD, You P, Cai J, Zang YS. The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base. Lung Cancer. 2018;123:70–5.
Kim Y, Lee B, Shim JH, Lee SH, Park WY, Choi YL, et al. Concurrent genetic alterations predict the progression to target therapy in EGFR-mutated advanced NSCLC. J Thorac Oncol. 2019;14:193–202.
Lee EB, Jin G, Lee SY, Park JY, Kim MJ, Choi JE, et al. TP53 mutations in Korean patients with non-small cell lung cancer. J Korean Med Sci. 2010;25:698–705.
Janus P, Toma-Jonik A, Vydra N, Mrowiec K, Korfanty J, Chadalski M, et al. Pro-death signaling of cytoprotective heat shock factor 1: upregulation of NOXA leading to apoptosis in heat-sensitive cells. Cell Death Differ. 2020;27:2280–92.
Borjan B, Kern J, Steiner N, Gunsilius E, Wolf D, Untergasser G.. Spliced XBP1 levels determine sensitivity of multiple myeloma cells to proteasome inhibitor bortezomib independent of the unfolded protein response mediator GRP78. Front Oncol. 2019;9:1530.
Gérecová G, Kopanicová J, Jaká P, Běhalová L, Juhásová B, Bhatia-Kiššová I, et al. BH3-only proteins Noxa, Bik, Bmf, and Bid activate Bax and Bak indirectly when studied in yeast model. FEMS Yeast Res. 2013;13:747–54.
Busacca S, Chacko AD, Klabatsa A, Arthur K, Sheaff M, Barbone D, et al. BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma. PLoS One. 2013;8:e65489.